PIK3CA-Mutated Cancers research hub

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

This study looks at a new drug, inavolisib, alone or with another drug, atezolizumab, for cancers with a specific change (PIK3CA mutation). It aims to see if they are safe and work well, especially for certain head and neck cancers.